ArticleDiscover oncology2025

ATF6 activation promotes tumorigenesis and drug resistance in diffuse large B-cell lymphoma (DLBCL) by regulating the mTOR/S6K signaling pathway.

Shuang Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.